Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06108037 · ClinicalTrials.gov registry record · NA

DHL Survey on Generative AI for MyChart Messaging

A NA study of Communication, sponsored by Duke University.

Completed
Registry status
NA
Development phase
1,454
Enrollment target
1
Study location

NCT06108037: Completed NA study of Communication, sponsored by Duke University.

NCT06108037 is a NA study of Communication that has completed, run by Duke University. The registered enrollment target is 1,454 participants, roughly in line with the 1,378-participant average among 34 other Communication trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06108037, a NA study of Communication, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
1,454 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand how patients feel about the use of computer programs to create responses when they send electronic messages to their doctors.

Primary Outcome

Likert-scale responses to satisfaction question: "I am satisfied with this interaction", on a scale from 1-5 with answer options of Strongly Disagree (1), Disagree (2), Neither agree nor disagree (3), Agree (4), and Strongly agree (5).

Conditions Studied

Interventions

  • BEHAVIORAL Generative AI for electronic communication and disclosure

Study Locations (1)

North Carolina

  • Duke University Health System - Durham

Trial Details

FieldValue
Enrollment Target 1,454 participants
Start Date 2023-10-31
Est. Completion 2023-12-11
Phase NA
Duke University

1,725 total trials

What the finished NCT06108037 record still lists

NCT06108037 is an interventional study that assigns participants to a tested intervention. Its 1,454 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,378-participant average among 34 other Communication trials with a reported enrollment target.

The record links to 1 condition, with Communication appearing as the primary indexed condition, and to 1 intervention - of which Generative AI for electronic communication and disclosure is the first listed.

NCT06108037 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06108037 about?

NCT06108037 is a clinical study titled "DHL Survey on Generative AI for MyChart Messaging". The purpose of this study is to understand how patients feel about the use of computer programs to create responses when they send electronic messages to their doctors.

What is the current status of trial NCT06108037?

This trial is currently completed. It is a NA study. The enrollment target is 1,454 participants. The study started on 2023-10-31. Estimated completion is 2023-12-11.

What conditions does trial NCT06108037 study?

This clinical trial studies the following conditions: Communication.

What interventions are being tested in trial NCT06108037?

The interventions under investigation include: Generative AI for electronic communication and disclosure (BEHAVIORAL).

Who is sponsoring clinical trial NCT06108037?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06108037 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Communication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06108037's enrollment target sits among peer trials

1,454 7th of 34 higher than 28 of 34 other Communication trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Communication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

  • NCT03936361 · 1,456 participants · Phase 3

    Statins In Intracerbral Hemorrhage

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05229341 · 1,450 participants · NA

    Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06108037, the US trial registry maintained by the National Library of Medicine. NCT06108037 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.